Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial

Introduction: Hyperuricemia is associated with chronic kidney disease (CKD) progression and poor cardiovascular outcomes. We studied the effect of febuxostat on estimated glomerular filtration rate (eGFR), proteinuria and monitored the safety profile of the medication. Material and Methods: This is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukri, Mohd Noor Azreey, Kong, Wei-Yen, Mustafar, Ruslinda, Shaharir, Syahrul Sazliyana, Shah, Shamsul Azhar, Abdul Gafor, Abdul Halim, Mohd, Rozita, Abdul Cader, Rizna, Kamaruzaman, Lydia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088214/
https://www.ncbi.nlm.nih.gov/pubmed/30108461
http://dx.doi.org/10.17179/excli2018-1256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088214/
https://www.ncbi.nlm.nih.gov/pubmed/30108461
http://dx.doi.org/10.17179/excli2018-1256

Ejemplares similares